Published in Infect Immun on February 25, 2008
Two genes on A/J chromosome 18 are associated with susceptibility to Staphylococcus aureus infection by combined microarray and QTL analyses. PLoS Pathog (2010) 1.17
Mechanisms of immune evasion in leishmaniasis. Adv Appl Microbiol (2013) 1.04
The role of leishmania proteophosphoglycans in sand fly transmission and infection of the Mammalian host. Front Microbiol (2012) 1.03
Toll-like receptors in leishmania infections: guardians or promoters? J Parasitol Res (2012) 1.03
Retracted Reactive oxygen species-triggered trophoblast apoptosis is initiated by endoplasmic reticulum stress via activation of caspase-12, CHOP, and the JNK pathway in Toxoplasma gondii infection in mice. Infect Immun (2012) 1.01
Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis. Infect Immun (2011) 0.91
Leishmania mexicana promastigotes inhibit macrophage IL-12 production via TLR-4 dependent COX-2, iNOS and arginase-1 expression. Mol Immunol (2011) 0.90
Human macrophage response to L. (Viannia) panamensis: microarray evidence for an early inflammatory response. PLoS Negl Trop Dis (2012) 0.88
Dendritic cells and parasites: from recognition and activation to immune response instruction. Semin Immunopathol (2016) 0.82
Leishmania mexicana infection induces IgG to parasite surface glycoinositol phospholipids that can induce IL-10 in mice and humans. PLoS Negl Trop Dis (2013) 0.80
Anti-Toll-like receptor 2 and 4 antibodies suppress inflammatory response in mice. Immunology (2014) 0.79
Screening of TNFα, IL-10 and TLR4 single nucleotide polymorphisms in individuals with asymptomatic and chronic cutaneous leishmaniasis in Colombia: a pilot study. BMC Infect Dis (2017) 0.75
Crosstalk between purinergic receptors and lipid mediators in leishmaniasis. Parasit Vectors (2016) 0.75
A defective TLR4 signaling for IFN-β expression is responsible for the innately lower ability of BALB/c macrophages to produce NO in response to LPS as compared to C57BL/6. PLoS One (2014) 0.75
Redundant and regulatory roles for TLRs in Leishmania infection. Clin Exp Immunol (2017) 0.75
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med (1999) 9.23
Advances in leishmaniasis. Lancet (2005) 8.95
TLR signaling. Semin Immunol (2007) 8.16
The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol (2002) 6.59
Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med (1993) 5.71
CD14 is required for MyD88-independent LPS signaling. Nat Immunol (2005) 5.20
Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med (2005) 3.85
TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med (2005) 3.44
The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol (2001) 3.21
Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol (2000) 3.10
Leishmaniasis: current status of vaccine development. Clin Microbiol Rev (2001) 2.62
Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol (2001) 2.60
A CD14-independent LPS receptor cluster. Nat Immunol (2001) 2.52
Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev (2005) 2.33
Type 1 interferon (IFNalpha/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. Immunity (1998) 2.22
The involvement of the major surface glycoprotein (gp63) of Leishmania promastigotes in attachment to macrophages. J Immunol (1986) 2.16
Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol Rev (2004) 2.12
Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol (2003) 2.08
CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol (2001) 1.95
Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii. J Immunol (2007) 1.95
Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol (2006) 1.94
The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci U S A (2003) 1.89
MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur J Immunol (2003) 1.82
TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol (2001) 1.79
Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun (2004) 1.65
NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. J Exp Med (2007) 1.57
Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect Immun (2002) 1.54
MD-2: the Toll 'gatekeeper' in endotoxin signalling. Trends Biochem Sci (2004) 1.53
Combinational clustering of receptors following stimulation by bacterial products determines lipopolysaccharide responses. Biochem J (2004) 1.52
Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J Immunol (2004) 1.49
Leishmania donovani lipophosphoglycan selectively inhibits signal transduction in macrophages. J Immunol (1991) 1.46
Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun (1995) 1.44
RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma-primed macrophages. Eur J Immunol (2006) 1.41
The role of the innate immune response in Th1 cell development following Leishmania major infection. J Leukoc Biol (1995) 1.40
T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. Exp Parasitol (1996) 1.36
R-form LPS, the master key to the activation ofTLR4/MD-2-positive cells. Eur J Immunol (2006) 1.27
Glycoinositolphospholipids of Leishmania major inhibit nitric oxide synthesis and reduce leishmanicidal activity in murine macrophages. Eur J Immunol (1995) 1.27
Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection. Infect Immun (2003) 1.16
Protection against progressive leishmaniasis by IFN-beta. J Immunol (2004) 1.12
Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol (1991) 1.12
The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J Immunol (2003) 1.05
Signaling pathways activated by microorganisms. Curr Opin Cell Biol (2007) 1.02
Recent developments in leishmaniasis. Curr Opin Infect Dis (2002) 1.01
The lipophosphoglycan of Leishmania and macrophage protein kinase C. Parasitol Today (1993) 0.96
TNF-alpha mediates the induction of nitric oxide synthase in macrophages but not in neutrophils in experimental cutaneous leishmaniasis. Eur J Immunol (2003) 0.95
Macrophage activation for antileishmanial defense by an apparently novel mechanism. J Immunol (1987) 0.94
Leishmania major proteophosphoglycan is expressed by amastigotes and has an immunomodulatory effect on macrophage function. Microbes Infect (1999) 0.91
Mutational and functional analysis of the Leishmania surface metalloproteinase GP63: similarities to matrix metalloproteinases. Parasitology (1994) 0.88
MD-2 binds to bacterial lipopolysaccharide. J Endotoxin Res (2000) 0.86
Biochemical characterization of the protective membrane glycoprotein GP46/M-2 of Leishmania amazonensis. Mol Biochem Parasitol (1991) 0.85
Biochemical and biological characterization of the protective Leishmania pifanoi amastigote antigen P-8. Infect Immun (2001) 0.84
A scaffold protein, AHNAK1, is required for calcium signaling during T cell activation. Immunity (2008) 1.78
Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect Immun (2003) 1.38
Heterogeneity, geographic distribution, and pathogenicity of serodemes of Leishmania viannia in Colombia. Am J Trop Med Hyg (2002) 1.23
Mechanisms of pathogenesis: differences amongst Leishmania species. Trans R Soc Trop Med Hyg (2002) 1.17
Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection. Infect Immun (2003) 1.16
Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation. Eur J Immunol (2010) 1.11
A Leishmania ortholog of macrophage migration inhibitory factor modulates host macrophage responses. J Immunol (2008) 1.09
A real-time polymerase chain reaction assay for the identification and quantification of American Leishmania species on the basis of glucose-6-phosphate dehydrogenase. Am J Trop Med Hyg (2008) 1.08
The DC-SIGN-related lectin LSECtin mediates antigen capture and pathogen binding by human myeloid cells. Blood (2007) 1.04
Role for nitric oxide in hookworm-associated immune suppression. Infect Immun (2008) 1.03
Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun (2005) 1.01
TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia). PLoS Negl Trop Dis (2011) 1.00
Leishmania pifanoi pathogenesis: selective lack of a local cutaneous response in the absence of circulating antibody. Infect Immun (2002) 0.97
Murine model of chronic L. (Viannia) panamensis infection: role of IL-13 in disease. Eur J Immunol (2010) 0.97
Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol (2008) 0.89
Human macrophage response to L. (Viannia) panamensis: microarray evidence for an early inflammatory response. PLoS Negl Trop Dis (2012) 0.88
The Abl and Arg kinases mediate distinct modes of phagocytosis and are required for maximal Leishmania infection. Mol Cell Biol (2012) 0.86
CD4 T cell activation by B cells in human Leishmania (Viannia) infection. BMC Infect Dis (2014) 0.81
CD4+ T cells play a dominant role in protection against New World leishmaniasis induced by vaccination with the P-4 amastigote antigen. Infect Immun (2005) 0.80
The flagellar protein FLAG1/SMP1 is a candidate for Leishmania-sand fly interaction. Vector Borne Zoonotic Dis (2015) 0.78